synthesi
sever
azapropellan
report
sever
novel
amin
display
lowmicromolar
activ
amantadineresist
strain
show
activ
amantadinesensit
strain
none
test
compound
inhibit
influenza
proton
channel
function
compound
show
cytotox
mdck
cell
scheme
simplif
dien
tetracyclo
azapropellan
gener
structur
ii
iii
letter
pubsacsorgacsmedchemlett
h
uman
influenza
viru
member
orthomyxovirida
caus
signific
morbid
mortal
particularli
infant
elderli
peopl
suffer
previou
patholog
immunodefici
capac
caus
widespread
epidem
relat
fast
droplet
transmiss
abil
escap
exist
immun
life
cycl
influenza
virus
well
document
viral
protein
regard
potenti
therapeut
target
howev
present
avail
drug
treatment
influenza
viru
infect
compris
ion
channel
blocker
amantadin
amt
rimantadin
chart
neuraminidas
inhibitor
oseltamivir
zanamivir
peramivir
laninamivir
take
account
current
circul
influenza
strain
resist
ion
channel
blocker
resist
neuraminidas
inhibitor
particular
oseltamivir
also
rise
novel
antiinfluenza
viru
drug
prefer
novel
mechan
action
urgent
need
influenza
viru
enter
target
cell
receptormedi
endocytosi
follow
acidinduc
fusion
viral
endosom
membran
fusion
event
mediat
conform
chang
influenza
hemagglutinin
ha
protein
trigger
low
ph
endosom
lumen
endosom
acid
ph
also
activ
membranespan
protein
act
proton
channel
conduct
proton
virion
interior
decreas
intravirion
ph
result
uncoat
viral
ribonucleoprotein
transfer
fusion
pore
cytoplasm
sinc
endosom
escap
viru
critic
depend
activ
proton
channel
ha
protein
dualli
act
agent
combin
blockad
channel
inhibitori
effect
ha
refold
appear
highli
attract
dual
approach
could
also
least
theori
increas
barrier
select
amt
resist
optim
amt
analogu
might
abl
exert
dual
pharmacolog
effect
provid
ha
inhibit
occur
similar
clinic
relev
compound
concentr
comparison
block
effect
amt
achiev
micromolar
concentr
wherea
effect
ha
refold
requir
much
higher
concentr
ie
rang
high
amt
concentr
achiev
vivo
standard
amt
drug
regimen
sinc
report
plasma
concentr
valu
amt
rang
henc
potenti
exploit
effect
amt
analogu
ha
refold
novel
deriv
potent
activ
ie
ic
valu
micromolar
rang
would
requir
wellknown
medicin
chemistri
drug
contain
cyclic
system
gener
worth
synthes
analogu
ring
open
expand
contract
one
unit
analogu
show
similar
activ
parent
compound
sometim
display
improv
pharmacokinet
profil
also
interest
simplifi
polycycl
activ
compound
remov
ring
previous
synthes
evalu
seri
ringcontract
ringexpand
ringrearrang
analogu
amt
rimantadin
although
found
sever
compound
interest
activ
channel
blocker
modifi
ha
refold
dual
agent
found
recent
report
dien
display
similar
valu
wildtyp
wt
amt
although
inact
amtresist
form
expect
amin
activ
cytopath
effect
cpe
assay
ec
amtsensit
strain
viru
wttype
channel
interestingli
amin
also
activ
ec
strain
viru
carri
two
characterist
amt
resist
mutat
protein
detail
studi
mechan
action
sever
relat
analogu
suggest
target
type
ha
effect
refold
thu
compound
may
consid
lead
dualli
act
compound
note
also
report
simplifi
analogu
dien
undecan
display
better
inhibit
wt
channel
ic
ic
slightli
potent
cpe
assay
ec
ec
amtsensit
strain
sharp
contrast
dien
also
activ
strain
azaundecan
inact
amtresist
strain
scheme
present
work
report
synthesi
antivir
activ
ringsimplifi
analogu
found
sever
novel
polycycl
amin
consider
higher
conform
freedom
display
low
micromolar
activ
amtresist
strain
howev
activ
markedli
subtyp
reagent
condit
naalh
och
ch
och
toluen
reflux
overnight
yield
yield
yield
yield
depend
none
compound
activ
amtsensit
influenza
strain
viru
seven
compound
includ
potent
amin
evalu
channel
blocker
unabl
inhibit
activ
wt
mutant
thu
suggest
interact
differ
target
viru
envisag
simplif
hexacycl
amin
may
lead
three
differ
propellan
scaffold
ii
iii
scheme
propellan
defin
tricycl
compound
three
ring
common
bond
note
use
propellan
scaffold
field
medicin
chemistri
rather
limit
fact
best
knowledg
use
azapropellan
unpreced
two
work
publish
connect
azapropellan
scaffold
synthesi
azapropellan
relat
gener
structur
straightforward
thu
reduct
known
imid
led
dien
yield
catalyt
hydrogen
led
azapropellan
yield
similar
fashion
start
known
imid
azapropellan
isol
yield
final
hydrolysi
known
anhydrid
led
diacid
yield
reaction
melt
urea
furnish
imid
subsequ
reduc
dien
scheme
three
compound
relat
gener
structur
ii
synthes
reduct
known
imid
furnish
synthesi
start
imid
previous
synthes
group
reaction
lihmd
gave
imid
yield
deprotect
imid
led
yield
influenza
virusinfect
mdck
cell
sever
compound
display
low
micromolar
activ
influenza
subtyp
compound
activ
influenza
subtyp
tabl
antivir
data
obtain
microscop
inspect
viral
cpe
day
post
infect
confirm
colorimetr
cell
viabil
assay
compound
prove
inact
influenza
b
viru
result
shown
two
compound
guanidin
cytotox
mdck
cell
analysi
data
tabl
reveal
follow
trend
first
within
seri
azapropellan
progress
satur
dien
alken
fulli
satur
increas
antivir
activ
strain
ec
respect
trend
previous
seen
go
dien
ec
fulli
satur
deriv
ec
interestingli
go
dien
tetramethyl
deriv
also
increas
activ
ec
vs
ec
unfortun
sever
attempt
carri
reduct
either
catalyt
hydrogen
diimid
unsuccess
like
due
steric
hindranc
second
ring
contract
azapropellan
azapropellan
improv
activ
compar
vs
introduct
methyliden
group
fivememb
ring
slightli
increas
activ
compar
vs
third
smallest
member
seri
azapropellan
inact
monomethyliden
deriv
howev
introduct
second
methyliden
group
led
activ
compound
ec
nearli
order
magnitud
potent
amt
rimantadin
final
except
compound
potent
amin
introduct
guanidin
group
clearli
deleteri
activ
lead
larg
inact
compound
wellknown
target
amt
rimantadin
influenza
viru
channel
protein
singl
mutat
suffici
render
viru
resist
drug
current
circul
strain
influenza
viru
subtyp
carri
mutat
urgent
need
develop
novel
antiinfluenza
drug
effect
common
amantadineresist
mutant
influenza
strain
use
cpe
assay
protein
carri
two
substitut
associ
amantadin
resist
ie
order
assess
target
novel
amin
protein
inhibitori
activ
seven
compound
test
channel
express
xenopu
oocyt
use
twoelectrod
voltag
clamp
tev
techniqu
none
abl
significantli
inhibit
activ
wt
amtresist
amtresist
mutant
indic
compound
show
antivir
activ
cpe
assay
viral
target
protein
combin
result
previous
report
dien
simpler
analogu
azapropellan
disclos
herein
seem
keep
conform
rigid
scaffold
suitabl
target
channel
previous
report
strong
activ
polycycl
amin
compound
strain
appear
relat
fact
viru
lower
fusion
ph
compar
strain
henc
strain
seem
sensit
slight
increas
endosom
ph
three
activ
compound
report
ie
evalu
cpe
assay
mutant
virus
increas
fusion
ph
due
specif
chang
ha
specif
mutant
virus
fusion
ph
compar
wt
viru
contain
mutat
ha
reduc
stabil
trimer
protein
none
three
compound
activ
mutant
form
data
shown
sum
synthes
fulli
character
evalu
seri
novel
azapropellan
deriv
strain
amtresist
viru
three
compound
endow
ec
valu
order
magnitud
lower
amt
compound
submicromolar
antivir
agent
cytotox
none
compound
activ
amtsensit
strain
mechan
action
unrel
channel
previou
compound
develop
group
seem
relat
low
fusion
ph
characterist
ha
viru
strain
amt
amantadin
bn
benzyl
cerium
ammonium
nitrat
cpe
cytopath
effect
ha
hemagglutinin
mdck
darbi
canin
kidney
mt
pmb
pmethoxybenzyl
wt
wildtyp
